Prognostic significance of copy-number alterations in multiple myeloma

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4585-4590

  Avet Loiseau, Hervé ^a   Li, Cheng ^a   Magrangeas, Florence ^a   Gouraud, Wilfried ^a   Charbonnel, Catherine ^a   Harousseau, Jean Luc ^a   Attal, Michel ^a   Marit, Gerald ^a   Mathiot, Claire ^a   Facon, Thierry ^a   Moreau, Philippe ^a   Anderson, Kenneth C ^a   Campion, Loïc ^a   Munshi, Nikhil C ^a   Minvielle, Stéphane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADVERSE OUTCOME; ARTICLE; CANCER CELL; CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME 12P; CHROMOSOME 14Q; CHROMOSOME 15; CHROMOSOME 16Q; CHROMOSOME 19; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 5; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE NUMBER; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOME ABERRATIONS; GENE DOSAGE; HUMANS; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 74549190701     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6136     Document Type: Article

References (43)

1. Smadja NV, Bastard C, Brigaudeau C, et al: Hypodiploidy is a major prognostic factorin multiple myeloma. Blood 98:2229-2238, 2001
2. Fonseca R, Debes-Marun CS, Picken EB, et al: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562-2567, 2003
3. Chng WJ, Kumar S, Vanwier S, et al: Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 67:2982-2989, 2007
4. Zojer N, Königsberg R, Ackermann J, et al: Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930, 2000
5. Facon T, Avet-Loiseau H, Guillerm G, et al: Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a very powerful myeloma staging system for patients receiving high dose therapy. Blood 97:1566-1571, 2001
6. Fonseca R, Harrington D, Oken MM, et al: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 62:715-720, 2002
7. Jenner MW, Leone PE, Walker BA, et al: Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in clinical outcome in multiple myeloma. Blood 110:3291-3300, 2007
8. Drach J, Ackermann J, Fritz E, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802-809, 1998
9. Chang H, Qi C, Yi QL, et al: p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358-360, 2005
10. Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495, 2007
11. Fonseca R, Van Wier SA, Chng WJ, et al: Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20:2034-2040, 2006
12. Chang H, Ning Y, Qi X, et al: Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 139: 51-54, 2007
13. Hanamura I, Stewart JP, Huang Y, et al: Frequent gain of chromosome band 1q21 in plasmacell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma. Blood 108:1724-1732, 2006
14. Moreau P, Facon T, Leleu X, et al: Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:1579-1583, 2002
15. Keats JJ, Reiman T, Maxwell CA, et al: In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101:1520-1529, 2003
16. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003
17. Avet-Loiseau H, Facon T, Grosbois B, et al: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191, 2002
18. Carrasco DR, Sukhdeo K, Protopopova M, et al: The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11:349-360, 2006
19. Lin M, Wei LJ, Sellers WR, et al: DChipSNP: Significance curve and clustering of SNP-arraybased loss-of-heterozygosity data. Bioinformatics 20:1233-1240, 2004
20. Beroukhim R, Lin M, Park Y, et al: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 5:e41, 2006
21. Olshen AB, Venkatraman ES, Lucito R, et al: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557-572, 2004
22. Cigudosa JC, Rao PH, Calasanz MJ, et al: Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 91:3007-3010, 1998
23. Liebisch P, Viardot A, Bassermann N, et al: Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 122: 193-201, 2003
24. Gutierrez NC, Garcia JL, Hernandez JM, et al: Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 104:2661-2666, 2004
25. Walker BA, Leone PE, Jenner MW, et al: Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108:1733-1743, 2006
26. Decaux O, Lodé L, Magrangeas F, et al: Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myelome. J Clin Oncol 26:4798-4805, 2008
27. Katayama Y, Sakai A, Oue N, et al: A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br J Haematol 120:223-234, 2003
28. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined signifi-cance, and normal bone marrow plasma cells. Blood 99:1745-1757, 2002
29. Guikema JE, Hovenga S, Vellenga E, et al: CD27 is heterogeneously expressed in multiple myeloma: Low CD27 expression in patients with highrisk disease. Br J Haematol 121:36-43, 2003
30. Moreau P, Robillard N, Jégo G, et al: Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 132:168-170, 2006
31. Morgan TK, Zhao S, Chang KL, et al: Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: An immunohistochemical analysis. Am J Clin Pathol 126:545-551, 2006
32. Guan D, Altan-Bonnet N, Parrott AM, et al: Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol Cell Biol 28:4629-4641, 2008
33. Nie YL, Ding PN, Kao R, et al: ADAR1interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of RNA editing. Mol Cell Biol 25:6956-6963, 2005
34. Patterson JB, Samuel CE: Expression and regulation by interferon of a double-stranded-RNAspecific adenosine deaminase from human cells: Evidence for two forms of the deaminase. Mol Cell Biol 15:5376-5388, 1995
35. Herbert A, Wagner S, Nickerson JA, et al: Induction of protein translation by ADAR1 within living cell nuclei is not dependent on RNA editing. Mol Cell 10:1235-1246, 2002
36. Shaughnessy JD Jr, Zhan F, Burington B, et al: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276-2284, 2007
37. Moreau P, Attal M, Garban F, et al: Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 21:2020-2024, 2007
38. Bryant B, Danaee H, Lichter D, et al: Highresolution assessment of chromosomal gains and losses in multiple myeloma tumors from bortezomib clinical trial. J Clin Oncol 26:471s, 2008 (suppl; abstr 8570)
39. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, et al: Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 28:772-783, 2008
40. Hartner JC, Walkley CR, Lu J, et al: ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 10:109-115, 2009
41. Xie P, Kraus ZJ, Stunz LL, et al: Roles of TRAF molecules in B lymphocyte function. Cytokine Growth Factor Rev 19:199-207, 2008
42. Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood 108:2020-2028, 2006
43. Annunziata CM, Davis RE, Demchenko Y, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007